THEO 310
Alternative Names: THEO-310Latest Information Update: 15 Sep 2023
At a glance
- Originator Theolytics
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 31 Jul 2023 THEO 310 is available for licensing as of 31 Jul 2023. https://www.theolytics.com/contact (Theolytics website, July 2023)
- 08 Jun 2023 Preclinical trials in Multiple myeloma in United Kingdom (IV)
- 08 Jun 2023 Pharmacodynamics data from preclinical trial in Multiple myeloma presented at the 28th Congress of the European Haematology Association (EHA-2023)